Mergenthaler, Philipp and Stetefeld, Henning R. and Dohmen, Christian and Kohler, Siegfried and Schoenenberger, Silvia and Boesel, Julian and Gerner, Stefan T. and Huttner, Hagen B. and Schneider, Hauke and Reichmann, Heinz and Fuhrer, Hannah and Berger, Benjamin and Zinke, Jan and Alberty, Anke and Kleiter, Ingo and Schneider-Gold, Christiane and Roth, Christian and Dunkel, Juliane and Steinbrecher, Andreas and Thieme, Andrea and Lee, De-Hyung and Linker, Ralf A. and Angstwurm, Klemens and Meisel, Andreas and Neumann, Bernhard (2022) Seronegative myasthenic crisis: a multicenter analysis. JOURNAL OF NEUROLOGY, 269 (7). pp. 3904-3911. ISSN 0340-5354, 1432-1459
Full text not available from this repository. (Request a copy)Abstract
Myasthenic crisis (MC) is a life-threatening condition for patients with myasthenia gravis (MG). Seronegative patients represent around 10-15% of MG, but data on outcome of seronegative MCs are lacking. We performed a subgroup analysis of patients who presented with MC with either acetylcholine-receptor-antibody-positive MG (AChR-MG) or seronegative MG between 2006 and 2015 in a retrospective German multicenter study. We identified 15 seronegative MG patients with 17 MCs and 142 AChR-MG with 159 MCs. Seronegative MCs were younger (54.3 +/- 14.5 vs 66.5 +/- 16.3 years; p = 0.0037), had a higher rate of thymus hyperplasia (29.4% vs 3.1%; p = 0.0009), and were more likely to be female (58.8% vs 37.7%; p = 0.12) compared to AChR-MCs. Time between diagnosis of MG and MC was significantly longer in seronegative patients (8.2 +/- 7.6 vs 3.1 +/- 4.4 years; p < 0.0001). We found no differences in duration of mechanical ventilation (16.2 +/- 15.8 vs 16.5 +/- 15.9 days; p = 0.94) and length of stay at intensive care unit (17.6 +/- 15.2 vs 17.8 +/- 15.4 days; p = 0.96), or in-hospital mortality (11.8% vs. 10.1%; p = 0.69). We conclude that MC in seronegative MG affects younger patients after a longer period of disease, but that crisis treatment efficacy and outcome do not differ compared to AChR-MCs.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | GRAVIS; MORTALITY; ANTIBODY; Myasthenia gravis; Myasthenic crisis; Antibody status; Seronegative; Outcome |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 08 Feb 2024 16:03 |
| Last Modified: | 08 Feb 2024 16:03 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58316 |
Actions (login required)
 |
View Item |
